Pulmonary hypertension (PH) remains a complex, progressive, and life-threatening disease

associated with substantial morbidity, impaired quality of life, and premature mortality.

Despite remarkable advances in diagnosis and treatment, PH continues to require early recognition,

accurate risk assessment, and a multidisciplinary management strategy.

Recent developments in imaging, haemodynamic evaluation, risk stratification, and targeted

therapies are rapidly transforming the care of PH patients, opening new opportunities for

personalized treatment and improved outcomes.

The Pulmonary Hypertension Meeting aims to provide an interactive forum where clinicians and

researchers can discuss current challenges and emerging evidence in the field. Particular attention

will be devoted to the most relevant therapeutic innovations, including novel disease-modifying

treatments and evolving management strategies across different PH populations.

Through expert lectures, case-based discussions, and scientific updates, the meeting will promote

evidence-based practice, multidisciplinary collaboration, and the translation of the latest scientific

advances into everyday clinical care.

PROGRAM

SATURDAY 26 SEPTEMBER 2026

SALUTI: Nicoletta Verì, Mauro Palmieri, Umberto Benedetto

09.00 - 9.20 Opening Remarks and course objectives

Sabina Gallina / Serena Rossi

 09.20 – 10.30 MORNING SESSION 1

Chairpersons: Francesco Cipollone/Francesca Santilli/Gianluca Primomo/Silvio Romano

Experts: Rossella Patea/Laura Martino/Cesare Mantini/Domenico D’Intino

9:20–09.30  Pulmonary Hypertension: A Rare or Common Disease? Clinical, healthcare, and prognostic impact analysis

                         Rosalinda Madonna

9:30–09:40 Modern Diagnostic Approaches

                       Paolo Ciarelli

9:40–09:50  The Central Role of Imaging in the Differential Diagnosis of Group 3 and Group 4  Diseases

                        Manuela Mereu

9:50–10:00  Right Heart Catheterisation: A Diagnostic Cornerstone from Werner Forssmann to the Present Day

                       Serena Rossi

10:00–10:10 Genetics

                        Laura Scelsi

10:10–10:30  Discussion

10:30 – 11.40 MORNING SESSION 2

Chairpersons: Sabina Gallina/Giulia Renda/Massimo di Marco

Experts: Fabrizio Ricci/Vincenzo Cicchitti/Fabio Fulgenzi

10:30–10:40 Focus on Congenital Heart Disease and Pulmonary Hypertension Through Clinical Cases

                        Paola Argiento

10:40-10:50  Evidence from the Light: Evidence-based Pulmonary Artery Denervation for PAH

                        Livio Giuliani

10:50–11.00 Focus on Group 2 Pulmonary Hypertension: Current Challenges

                         Stefano Ghio

11:00 – 11:10 Focus on Chronic Thromboembolic Pulmonary Hypertension: The Pivotal Role of

                           Medical Therapy Alongside Surgery and BPA

                          Livio Giuliani

11:10-11:40 Discussione

11:40–11:50 Coffee Break

LATE MORNING SESSION

Chairpersons: Roberto Badagliacca/Stefano Ghio/Livio Giuliani

Experts: Paolo Ciarelli/Angelo Mazzei/Letizia di Fabio

11:50–12:00   A first-in-class Activin-Signalling Inhibitor: A Therapeutic Revolution Pharmacological background and the STELLAR study

  Carmine Dario Vizza

12:00–12:10  HYPERION and ZENITH: Analysis of the Trials That May Change Everything

                          Michele D’Alto (contributo registrato)

12:10 -12.55  Clinical Cases on the novel pathway-modifying treatment

                          Serena Rossi/ Laura Scelsi/tbd

12:55-13:25 Discussion

13:25-13:40  Best Clinical Case Awards

Voting

13:40–14:30 Lunch

 AFTERNOON SESSION

Chairpersons: Paolo Amerio/Raffaele Zicolella /Dario Vizza/Franco de Remigis

Experts: Marco Mascellanti/Roberta Aquilani/ Miriam Di Penta

14:30–14:45 Pitfalls in the Diagnosis of Pulmonary Arterial Hypertension Associated with Scleroderma

                         Emanuela Sabatini

14:45–15:00  Therapeutic Management of Patiens at intermediate risk

                           Giuseppe Galgano

15:00–15:15 Current Role of Prostanoid Therapy

                         Roberto Badagliacca

15:15-15:35 Lectio Magistralis: CTEPH Management in 2026: Integrating Surgical and Percutaneous

Therapies

                      Andrea Maria D’Armini

15:35–16:00 Discussion

16:00–16.20  Closing Remarks and take home message

              Sabina Gallina/Serena Rossi

L’acquisizione dei CREDITI FORMATIVI ECM è subordinata a:

• Partecipazione obbligatoria ad almeno il 90% del corso
• Compilazione online della “Scheda di valutazione evento” (OBBLIGATORIA) e del “Questionario di rilevazione dei fabbisogni formativi” (facoltativa)
• Superamento della verifica di apprendimento (questionario online a doppia randomizzazione)
• Download diretto (solo al termine del percorso) dell’Attestato ECM